Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease

Anamitra Ghosh, Avik Roy, Joanna Matras, Saurav Brahmachari, Howard Eliot Gendelman, Kalipada Pahan

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

Parkinson's disease (PD) is second only to Alzheimer's disease as the most common devastating human neurodegenerative disorder. Despite intense investigation, no interdictive therapy is available for PD. We investigated whether simvastatin, a Food and Drug Administration-approved cholesterol-lowering drug, could protect against nigrostriatal degeneration after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication to model PD in mice. First, MPP+ induced the activation of p21ras and nuclear factor-κB (NF-κB) in mouse microglial cells. Inhibition of MPPκ-induced activation of NF-κB by Δp21ras, a dominant-negative mutant of p21ras, supported the involvement of p21ras in MPP+-induced microglial activation of NF-κB. Interestingly, simvastatin attenuated activation of both p21 ras and NF-κB in MPP+-stimulated microglial cells. Consistently, we found a very rapid activation of p21ras in vivo in the substantia nigra pars compacta of MPTP-intoxicated mice. However, after oral administration, simvastatin entered into the nigra, reduced nigral activation of p21ras, attenuated nigral activation of NF-κB, inhibited nigral expression of proinflammatory molecules, and suppressed nigral activation of glial cells. These findings paralleled dopaminergic neuronal protection, normalized striatal neurotransmitters, and improved motor functions in MPTP-intoxicated mice. Similarly, pravastatin, another cholesterol-lowering drug, suppressed microglial inflammatory responses and protected dopaminergic neurons in MPTP-intoxicated mice, but at levels less than simvastatin. Furthermore, both the statins administered 2 d after initiation of the disease were still capable of inhibiting the demise of dopaminergic neurons and concomitant loss of neurotransmitters, suggesting that statins are capable of slowing down the progression of neuronal loss in the MPTP mouse model. Therefore, we conclude that statins may be of therapeutic benefit for PD patients.

Original languageEnglish (US)
Pages (from-to)13543-13556
Number of pages14
JournalJournal of Neuroscience
Volume29
Issue number43
DOIs
StatePublished - Oct 28 2009

Fingerprint

Simvastatin
Dopaminergic Neurons
Parkinson Disease
Substantia Nigra
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Neurotransmitter Agents
Cholesterol
Proto-Oncogene Proteins p21(ras)
Corpus Striatum
Pravastatin
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
United States Food and Drug Administration
Neuroglia
Neurodegenerative Diseases
Pharmaceutical Preparations
Oral Administration
Alzheimer Disease
4-phenyl-1,2,3,6-tetrahydropyridine
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. / Ghosh, Anamitra; Roy, Avik; Matras, Joanna; Brahmachari, Saurav; Gendelman, Howard Eliot; Pahan, Kalipada.

In: Journal of Neuroscience, Vol. 29, No. 43, 28.10.2009, p. 13543-13556.

Research output: Contribution to journalArticle

Ghosh, Anamitra ; Roy, Avik ; Matras, Joanna ; Brahmachari, Saurav ; Gendelman, Howard Eliot ; Pahan, Kalipada. / Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. In: Journal of Neuroscience. 2009 ; Vol. 29, No. 43. pp. 13543-13556.
@article{316d687bc3f6434fb44498407a8fc52b,
title = "Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease",
abstract = "Parkinson's disease (PD) is second only to Alzheimer's disease as the most common devastating human neurodegenerative disorder. Despite intense investigation, no interdictive therapy is available for PD. We investigated whether simvastatin, a Food and Drug Administration-approved cholesterol-lowering drug, could protect against nigrostriatal degeneration after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication to model PD in mice. First, MPP+ induced the activation of p21ras and nuclear factor-κB (NF-κB) in mouse microglial cells. Inhibition of MPPκ-induced activation of NF-κB by Δp21ras, a dominant-negative mutant of p21ras, supported the involvement of p21ras in MPP+-induced microglial activation of NF-κB. Interestingly, simvastatin attenuated activation of both p21 ras and NF-κB in MPP+-stimulated microglial cells. Consistently, we found a very rapid activation of p21ras in vivo in the substantia nigra pars compacta of MPTP-intoxicated mice. However, after oral administration, simvastatin entered into the nigra, reduced nigral activation of p21ras, attenuated nigral activation of NF-κB, inhibited nigral expression of proinflammatory molecules, and suppressed nigral activation of glial cells. These findings paralleled dopaminergic neuronal protection, normalized striatal neurotransmitters, and improved motor functions in MPTP-intoxicated mice. Similarly, pravastatin, another cholesterol-lowering drug, suppressed microglial inflammatory responses and protected dopaminergic neurons in MPTP-intoxicated mice, but at levels less than simvastatin. Furthermore, both the statins administered 2 d after initiation of the disease were still capable of inhibiting the demise of dopaminergic neurons and concomitant loss of neurotransmitters, suggesting that statins are capable of slowing down the progression of neuronal loss in the MPTP mouse model. Therefore, we conclude that statins may be of therapeutic benefit for PD patients.",
author = "Anamitra Ghosh and Avik Roy and Joanna Matras and Saurav Brahmachari and Gendelman, {Howard Eliot} and Kalipada Pahan",
year = "2009",
month = "10",
day = "28",
doi = "10.1523/JNEUROSCI.4144-09.2009",
language = "English (US)",
volume = "29",
pages = "13543--13556",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "43",

}

TY - JOUR

T1 - Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease

AU - Ghosh, Anamitra

AU - Roy, Avik

AU - Matras, Joanna

AU - Brahmachari, Saurav

AU - Gendelman, Howard Eliot

AU - Pahan, Kalipada

PY - 2009/10/28

Y1 - 2009/10/28

N2 - Parkinson's disease (PD) is second only to Alzheimer's disease as the most common devastating human neurodegenerative disorder. Despite intense investigation, no interdictive therapy is available for PD. We investigated whether simvastatin, a Food and Drug Administration-approved cholesterol-lowering drug, could protect against nigrostriatal degeneration after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication to model PD in mice. First, MPP+ induced the activation of p21ras and nuclear factor-κB (NF-κB) in mouse microglial cells. Inhibition of MPPκ-induced activation of NF-κB by Δp21ras, a dominant-negative mutant of p21ras, supported the involvement of p21ras in MPP+-induced microglial activation of NF-κB. Interestingly, simvastatin attenuated activation of both p21 ras and NF-κB in MPP+-stimulated microglial cells. Consistently, we found a very rapid activation of p21ras in vivo in the substantia nigra pars compacta of MPTP-intoxicated mice. However, after oral administration, simvastatin entered into the nigra, reduced nigral activation of p21ras, attenuated nigral activation of NF-κB, inhibited nigral expression of proinflammatory molecules, and suppressed nigral activation of glial cells. These findings paralleled dopaminergic neuronal protection, normalized striatal neurotransmitters, and improved motor functions in MPTP-intoxicated mice. Similarly, pravastatin, another cholesterol-lowering drug, suppressed microglial inflammatory responses and protected dopaminergic neurons in MPTP-intoxicated mice, but at levels less than simvastatin. Furthermore, both the statins administered 2 d after initiation of the disease were still capable of inhibiting the demise of dopaminergic neurons and concomitant loss of neurotransmitters, suggesting that statins are capable of slowing down the progression of neuronal loss in the MPTP mouse model. Therefore, we conclude that statins may be of therapeutic benefit for PD patients.

AB - Parkinson's disease (PD) is second only to Alzheimer's disease as the most common devastating human neurodegenerative disorder. Despite intense investigation, no interdictive therapy is available for PD. We investigated whether simvastatin, a Food and Drug Administration-approved cholesterol-lowering drug, could protect against nigrostriatal degeneration after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication to model PD in mice. First, MPP+ induced the activation of p21ras and nuclear factor-κB (NF-κB) in mouse microglial cells. Inhibition of MPPκ-induced activation of NF-κB by Δp21ras, a dominant-negative mutant of p21ras, supported the involvement of p21ras in MPP+-induced microglial activation of NF-κB. Interestingly, simvastatin attenuated activation of both p21 ras and NF-κB in MPP+-stimulated microglial cells. Consistently, we found a very rapid activation of p21ras in vivo in the substantia nigra pars compacta of MPTP-intoxicated mice. However, after oral administration, simvastatin entered into the nigra, reduced nigral activation of p21ras, attenuated nigral activation of NF-κB, inhibited nigral expression of proinflammatory molecules, and suppressed nigral activation of glial cells. These findings paralleled dopaminergic neuronal protection, normalized striatal neurotransmitters, and improved motor functions in MPTP-intoxicated mice. Similarly, pravastatin, another cholesterol-lowering drug, suppressed microglial inflammatory responses and protected dopaminergic neurons in MPTP-intoxicated mice, but at levels less than simvastatin. Furthermore, both the statins administered 2 d after initiation of the disease were still capable of inhibiting the demise of dopaminergic neurons and concomitant loss of neurotransmitters, suggesting that statins are capable of slowing down the progression of neuronal loss in the MPTP mouse model. Therefore, we conclude that statins may be of therapeutic benefit for PD patients.

UR - http://www.scopus.com/inward/record.url?scp=70350555275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350555275&partnerID=8YFLogxK

U2 - 10.1523/JNEUROSCI.4144-09.2009

DO - 10.1523/JNEUROSCI.4144-09.2009

M3 - Article

C2 - 19864567

AN - SCOPUS:70350555275

VL - 29

SP - 13543

EP - 13556

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 43

ER -